Salix Pharmaceuticals Announces 3Q2009 Financial Results Conference Call and Webcast

The Company will host a conference call at 5:00 p.m. ET, on Monday,
November 9, 2009. Interested parties can access the conference call by
way of web cast or telephone. The live web cast will be available at www.salix.com.
A replay of the web cast will be available at the same location. The
telephone numbers to access the live conference call are (888) 500-6970
(U.S. and Canada) or (719) 325-2292 (international.) The telephone
numbers to access the replay of the call are (888) 203-1112 (U.S. and
Canada) or (719) 457-0820 (international). The access code for the
replay is 5047001.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina,
develops and markets prescription pharmaceutical products for the
treatment of gastrointestinal diseases. Salix's strategy is to
in-license late-stage or marketed proprietary therapeutic drugs,
complete any required development and regulatory submission of these
products, and market them through the Company's gastroenterology
specialty sales and marketing team.

Salix markets XIFAXAN(R) (rifaximin) tablets 200 mg, OSMOPREP(R)
(sodium phosphate monobasic monohydrate, USP and sodium phosphate
dibasic anhydrous, USP) Tablets, MOVIPREP(R) (PEG 3350, Sodium
Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and
Ascorbic Acid for Oral Solution), VISICOL(R) (sodium phosphate
monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Tablets, APRISO(TM) (mesalamine) extended-release capsules 0.375 g.,
METOZOLV(TM) ODT (metoclopramide HCl), PEPCID(R) (famotidine) for
Oral Suspension, Oral Suspension DIURIL(R) (Chlorothiazide),
AZASAN(R) Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC(R)
2.5% (Hydrocortisone Cream, USP), ANUSOL-HC(R) 25 mg
Suppository (Hydrocortisone Acetate), PROCTOCORT(R) Cream
(Hydrocortisone Cream, USP) 1% and PROCTOCORT(R) Suppository
(Hydrocortisone Acetate Rectal Suppositories) 30 mg. Crofelemer,
budesonide foam and rifaximin for additional indications are under
development.

For full prescribing information on Salix products, please visit www.salix.com
or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol
"SLXP."

For more information please visit our web site at www.salix.com
. Information on our web site is not incorporated in our SEC filings.

SOURCE: Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals, Ltd. 
Adam C. Derbyshire, Executive Vice President and Chief Financial Officer or 
G. Michael Freeman, Associate Vice President, Investor Relations 
and Corporate Communications, 919-862-1000

For full details on Salix Pharmaceuticals Ltd (SLXP) SLXP. Salix Pharmaceuticals Ltd (SLXP) has Short Term PowerRatings at TradingMarkets. Details on Salix Pharmaceuticals Ltd (SLXP) Short Term PowerRatings is available at This Link.